X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Nicole Longo

Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Recent Posts

WTAS: Inflation Reduction Act already impacting R&D decisions

By Nicole Longo  |    January 17, 2023
The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...   Read More

340B program continues to drive shift in care to more expensive hospital settings

By Nicole Longo  |    December 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...   Read More

The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

By Nicole Longo  |    November 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times...   Read More

Medicare Part D open enrollment and what recent changes mean for beneficiaries

By Nicole Longo  |    November 17, 2022
It’s that time of year again: Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their...   Read More

New government price setting policy threatens post-approval research

By Nicole Longo  |    November 10, 2022
Have you ever noticed that one medicine might be used to treat two, three, seven different conditions? That’s the result of significant additional research and investment, including lengthy and...   Read More

Three ways 340B is failing vulnerable patients

By Nicole Longo  |    October 20, 2022
The 340B Drug Pricing Program is 30 years old this year, but as The New York Times recently spelled out, the program has become a profit engine for large health systems over the years instead of a...   Read More

Many seniors are paying more for Part D medicines than their insurer

By Nicole Longo  |    October 18, 2022
For seniors who rely on Medicare Part D, the out-of-pocket costs for medicines can sometimes be a barrier. Insurers and pharmacy benefit managers (PBMs) continue to shift more and more costs to...   Read More

If patients aren’t benefiting from the 340B program, who is?

By Nicole Longo  |    October 6, 2022
The 340B Drug Pricing Program was designed to help vulnerable patients improve access to their medicines through manufacturer discounts to specific safety-net, non-profit hospitals and federally...   Read More

New data: The 340B program is driving up costs for patients and our health care system

By Nicole Longo  |    September 15, 2022
Guess what? The 340B program grew, yet again, hitting a whopping $43.9 billion in sales at the discounted 340B price in 2021. But there has not been evidence of corresponding growth in care provided...   Read More

Word of the Month: 340B covered entity

By Nicole Longo  |    August 29, 2022
What is a 340B covered entity?   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates